Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin: The Alpha And The Omega

AstraZeneca is stopping a large clinical study of its fish-oil-derived heart drug, Epanova. That’s good news for Amarin and Amarin stock.

AstraZeneca’s Loss is Amarin’s Big Gain This Year

AstraZeneca

Acasti Pharma

Shares of Amarin Corp. PLC AMRN, +4.80% rose 4.8% in active afternoon trading Monday, after makers of drugs that rival Amarin's Vascepa, which is used to lower the risk of cardiovascular events in patients with high triglyceride levels reported disappointing trial results.

Amarin's stock surges, as rival drugs from AstraZeneca, Acasti disappoint

The British drugmaker throws in the towel on a study that could have positioned Epanova to compete against Amarin's Vascepa.

Good News for Amarin: AstraZeneca Abandoning its Fish Oil Pill

Amarin stock popped Monday after rivals AstraZeneca and Acasti Pharma reported disappointing outcomes for their Vascepa-rivaling high triglycerides treatments.

This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled

Recent survey of healthcare professionals reveals need for more education and dialogue on scientific advances and regulatory actions to ensure optimal cardiovascular health care Recent survey of healthcare professionals reveals need for more education and dialogue on scientific advances and regulatory actions to ensure optimal cardiovascular health care

Amarin Launches True To Your Heart, a Campaign to Educate People on Persistent Cardiovascular Risk

Bristol-Myers

Blackstone Group

Clovis Oncology

Journey Medical Corp

Intuitive Surgical

Johnson & Johnson

Kaleido Biosciences Inc

Eli Lilly

Medtronic

Roche Holding AG

Sanofi

Sorrento Therapeutics Inc

The Super Bowl of healthcare kicked off early for these companies.

All the 2020 Pre-JPM News Healthcare Investors Need to Know

Amarin stock is set for growth with Vascepa approval and sales outlook for 2020 predicting revenue will eventually hit billions of dollars
The post Amarin Stock Bouncing Back After Revised Results and 2020 Guidance appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					2 Toxic Pot Stocks You Should Avoid				
			
					
				
					The Top 15 Stocks to Buy in 2020				
			
					
				
					The 7 Most Important Companies That Didn't Survive the 2010s				
			
					
				
					4 Mega-Tech Stocks Reaching for the Sky

Amarin Stock Bouncing Back After Revised Results and 2020 Guidance

AbbVie

Cardinal Health

Gilead Sciences

Novo Nordisk

Thermo Fisher Scientific

Politicians have investors in healthcare stocks nervous as the 2020 election nears. Here's a guide to which firms are good choices and which you should avoid.

7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount

Arrowhead Pharmaceuticals

Intercept Pharma

Flushed with cash, bigger biotech stocks are on the hunt. These 3 smaller drug makers could be the next buyout targets in the new year.

3 Biotech Stocks to Bank on for Buyouts in 2020

Much of the upside from flagship drug Vascepa is already priced into Amarin stock. Wait for a pullback before buying AMRN stock.

All Bets Are Off for Amarin Stock

FDA approval of Vascepa in use for cardiovascular events just widened Amarin’s revenue potential. Amarin stock should have a banner 2020.

A Recent FDA Approval Will Be Huge in Moving Amarin Stock

Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020.

Amarin Posts '19 Preliminary Results, Gives 2020 Expense View

The company gave investors some unaudited numbers from the most recent quarter on how its fish oil-derived medicine performed. And its newly expanded label means this year will be even bigger.

Amarin Reports Preliminary Vascepa Sales, Projects Further Growth In 2020

Amarin Corp. AMRN, +1.34% said Tuesday that it expects 2019 revenue to be at or above the high end of its guidance range of $410 million to $425 million, while the FactSet consensus is in the middle of that range at $417.5 million.

Amarin raises 2019 revenue outlook, to double sales team as it 'aggressively' launches Vascepa in the U.S.

Unaudited Full-Year 2019 Net Total Revenue Estimated At or Slightly Above Upper-End of Prior Guidance of $410 to $425 Million

Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook

Matinas BioPharma Hlds

Matinas And Amarin, And Other News And Issues: The Good, Bad, And Ugly Of Biopharma

CRISPR Therapeutics

Vertex Pharmaceuticals

Exponential growth is on the horizon for these companies. Investors should take note.

3 High-Growth Stocks That Can Soar

Amarin stock has been on fire in 2019, but the reaction to its latest news was discouraging. Is that a buying opportunity or a warning sign?

Is Amarin Stock a Top Pick for 2020?

Amarin stock is beating the indices and its sector etf's for a reason. Its chart suggests that there is an exciting move brewing.

Amarin Stock Primed for New Highs

Carvana

EverBank Financial

Shopify

Here's a starter position with four high-growth stocks in a variety of industries.

Where to Invest  $10,000 Right Now

Global Blood Therapeutics

These companies could kick off the year with big announcements and deliver gains to savvy investors.

3 Top Biotech Stocks to Buy in January

Domino's Pizza

iRobot

Rite Aid

Target

Under Armour

The M&A market could bounce-back in 2020, and as it does, investors should keep an eye on these seven buyout targets.

7 Buyout Targets to Watch For 2020

Pharmaceutical companies are always difficult investment propositions, and Amarin shares proved why with its perhaps unjustifiably hyped drug Vascepa.
The post Amarin Risks Getting Exposed as a Paper Tiger appeared first on InvestorPlace.

Amarin Risks Getting Exposed as a Paper Tiger

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan.  02, 2020  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) is pleased to announce that Health Canada has approved the use of VASCEPA® (icosapent ethyl) to reduce the risk  of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor. This is the first and only approval by Health Canada of any drug for this important indication. The approval was achieved through Amarin’s commercial licensee for VASCEPA in Canada, HLS Therapeutics, Inc. (“HLS”). Pursuant to an agreement announced in 2017, HLS has exclusive commercial rights to VASCEPA in the Canadian market.  

News for Amarin Corporation Plc Stock (AMRN)